Am-Pharma

Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury. Its lead program targets acute kidney injury in critically ill patients, with additional research exploring broader applications in organ protection.

By addressing key drivers of inflammation and tissue damage, AM-Pharma aims to improve survival and recovery outcomes.